SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 92 filers reported holding SPERO THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $18,625 | -25.5% | 10,766 | -13.9% | 0.00% | – |
| Q3 2022 | $25,000 | +31.6% | 12,506 | -52.3% | 0.00% | – |
| Q2 2022 | $19,000 | -94.2% | 26,228 | -30.5% | 0.00% | – |
| Q1 2022 | $328,000 | -31.5% | 37,728 | +26.2% | 0.00% | -100.0% |
| Q4 2021 | $479,000 | -45.0% | 29,886 | -36.8% | 0.00% | 0.0% |
| Q3 2021 | $871,000 | +27.2% | 47,316 | -3.6% | 0.00% | 0.0% |
| Q2 2021 | $685,000 | -4.1% | 49,069 | +1.0% | 0.00% | 0.0% |
| Q1 2021 | $714,000 | -24.8% | 48,569 | -0.9% | 0.00% | -50.0% |
| Q4 2020 | $950,000 | +69.3% | 48,988 | -2.5% | 0.00% | +100.0% |
| Q3 2020 | $561,000 | -3.1% | 50,268 | +17.5% | 0.00% | 0.0% |
| Q2 2020 | $579,000 | +63.1% | 42,787 | -2.7% | 0.00% | 0.0% |
| Q1 2020 | $355,000 | +22.8% | 43,996 | +46.5% | 0.00% | 0.0% |
| Q4 2019 | $289,000 | +110.9% | 30,027 | +131.9% | 0.00% | – |
| Q3 2019 | $137,000 | – | 12,949 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Associates IX, LLC | 1,353,303 | $1,637,497 | 13.93% |
| Anson Funds Management LP | 4,159,572 | $5,033,082 | 1.01% |
| OUP Management Co., LLC | 249,070 | $301,375 | 0.68% |
| Atlas Venture Life Science Advisors, LLC | 1,013,438 | $1,226,260 | 0.19% |
| Murchinson Ltd. | 862,700 | $1,043,867 | 0.13% |
| Alphabet Inc. | 889,979 | $1,076,874 | 0.07% |
| AWM Investment Company, Inc. | 333,400 | $403,414 | 0.06% |
| DAFNA Capital Management LLC | 125,000 | $151,250 | 0.05% |
| Novo Holdings A/S | 468,902 | $567,371 | 0.04% |
| XTX Topco Ltd | 58,368 | $70,625 | 0.01% |